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Abstract
Only very limited data are available concerning patient
adherence to antithrombotic medication intended to pre-
vent a recurrent stroke. Reduced adherence and com-
pliance could significantly influence the effects of any
stroke prevention strategies. This study from a large
stroke data bank provides representative data concern-
ing the rate of stroke victims adhering to their recom-
mended preventive medication. During a 2-year period
beginning January 1, 1998, all patients with acute stroke
or TIA in 23 neurological departments with an acute
stroke unit were included in the German Stroke Data
Bank. Data were collected prospectively, reviewed, vali-
dated and processed in a central data management unit.
Only 12 centers with a follow-up rate of 80% or higher
were included in this evaluation. 3,420 patients were fol-
lowed up after 3 months, and 2,640 patients were fol-
lowed up one year after their stroke. After one year, 96%
of all patients reported still adhere to at least one medical
stroke prevention strategy. Of the patients receiving as-
pirin at discharge, 92.6% reported to use that medication
after 3 months and 84% after one year, while 81.6 and
61.6% were the respective figures for clopidogrel, and
85.2 and 77.4% for oral anticoagulation. Most patients
who changed medication switched from aspirin to clopi-
dogrel. Under the conditions of this observational study,
adherence to stroke prevention strategies is excellent.
The highest adherence rate is noticed for aspirin and
oral anticoagulation. After one year, very few patients
stopped taking stroke preventive medication.
Copyright © 2003 S. Karger AG, Basel
Various drugs are currently used for secondary stroke
prevention, e.g. aspirin, clopidogrel, ticlopidine and aspi-
rin plus dipyridamole [1]. Current conventions and fo-
rums focus on the best strategies for stroke prevention [2–
5]. Recommendations from various experts are based on
small to moderate differences between various drugs.
These differences result from large-scale trials sponsored
by pharmaceutical companies (e.g. CAPRIE, ESPS-2) [6,
7]. Very few data on patient adherence are available for
secondary stroke preventive medication. In 1994, Ko-
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miya et al. reported the results of a study in 159 outpa-
tients and 79 inpatients [8]. Seventeen outpatients (about
10%) had inadequate thrombocyte aggregation inhibition
and were considered non-compliant. Adherence to anti-
platelet drugs, as well as to antihypertensive and lipid low-
ering drugs, is subject of numerous studies [9–16]. While
80% adherence to antihypertensive drugs after one year is
considered satisfactory, reductions up to 50% after one
year are reported [17]. In the Aspirin Myocardial Infarc-
tion Study, 85% of the patients taking aspirin and 78%
treated with a placebo kept their medication [18]. A major
risk factor for recurring vascular events or death is non-
adherence to medication. This also causes major econom-
ic problems. Non-compliance accounted for more than
half of the drug failures under antihypertensive treatment
[19]. Adherence to a prescribed drug, moreover, is per-
haps related to other factors such as patient’s education
and attitude to disease [20], perceived or experienced side
effects [21, 22], patient specific reminders [23], medical
regimen with a convenient intake frequency [24], adher-
ence control and physician’s attitude regarding therapy
[23]. Major problems also include potential side effects
and the patient’s non-verbalized anxiety towards any
chemical agent [23]. Also, cerebrovascular disease-related
cognitive impairment can reduce the ability to adhere to a
specific medication [26]. Finally, physicians, too, reliant
upon the limited means of the German health care sys-
tem, cannot always afford to prescribe costly new drugs,
like the thienopyridines.
Various methods to detect adherence to a given drug
were implemented, e.g. direct measurement of the drugs
or their metabolites in blood, urine or saliva, count of
remaining and distributed pills, record of drug prescrip-
tion, and self-reports of the physicians or patients [27].
Recently, new computerized containers were additionally
used for drug adherence control [17, 28]. Self-reports
could overestimate drug adherence when compared to
more objective methods such as drug inventory or plasma
levels [29]. This study, planned as a part of the German
Stroke Data Bank, interviewed patients by telephone to
detect their drug adherence. We present the data on stroke
preventive strategies as self-reported after 3 months and 1
year following an index stroke event.
Patients and Methods
Data were collected prospectively within the German Stroke
Data Bank of the Stiftung Deutsche Schlaganfall-Hilfe in 23 neuro-
logical departments during a 2-year period beginning January 1,
1998. All hospitals have an acute stroke unit and in most cases also a
neurological intensive care unit. They serve areas of 100,000 to
1 million inhabitants and are the principle health care providers for
stroke patients in their regions. Cranial CT or MRI, extra- and trans-
cranial Doppler sonography and/or angiography of brain-supplying
arteries (including CT or MR angiography), ECG and/or ECG moni-
toring, basic blood tests and additional laboratory investigations
were performed in all patients. The majority of patients was exam-
ined by transthoracic or transesophageal echocardiography. Local
review boards approved the protocol of the Stroke Data Bank, and
most patients consented that, apart from the medical data, their per-
sonal records be transferred and kept in the central data management
center. In accordance with extensive guidelines, the data collected
included age, sex, time of event and admission, risk factors, vascular
comorbidities, prior medication, baseline neurological impairments,
as rated on the National Institute of Health Stroke Scale (NIH-SS),
functional independence pre-stroke and after admission, as rated on
the Barthel Index and modified Rankin Scale, results of ancillary
tests, morphology and localization of infarction, TOAST classifica-
tion of ischemic stroke, acute therapy, onset and severity of medical
plus neurological complications, secondary prevention, and neuro-
logical impairments as well as functional independence at discharge.
The outcome, assessed twice, first at 3 and later at 12 months,
included causes of death, recurrent stroke, compliance with second-
ary prevention, risk factor modification, and functional indepen-
dence, as rated on the Barthel Index and modified Rankin Scale.
All data were collected on a standardized questionnaire by the
local neurologists. Scores were quantified by local researchers who
were familiar with the NIH-SS from other clinical trials or from the
NIH-SS training video.
Between 1998 and 1999, a total of 8,200 patients with ischemic
stroke or TIA were entered into the data bank. In order to assure
accurate data, only patients from such centers were considered that
had followed-up more than 80 % of their patients. 12 centers – Min-
den, München-Harlaching, Essen, Heidelberg, Leipzig, Benjamin
Franklin Berlin, Bonn, München-Grosshadern, Frechen, Jena and
Bielefeld – met these criteria and registered a total of 5,219 patients.
215 patients (4.1%) died in the admitting hospital and 219 (4.2%)
had no data available on secondary prevention at discharge. Of the
remaining 4,785 patients, secondary prevention could be assessed at
first follow-up (within 70–180 days after the initial event) in 3,420
patients (71.5%), while 204 patients (4.3%) had died since discharge
from the hospital and 1,161 patients (24.3%) were either unable to be
reached or unable to provide any information on their secondary pre-
vention (see fig. 1).
Of the 3,420 patients with information available at the first fol-
low-up, the secondary prevention could be assessed in 2,640 (77.2%)
at a second follow-up (within 330 and 450 days after the event). 155
patients (4.5%) had died since the first follow-up, and 625 patients
(18.3%) could not be reached during this time or could provide no
information on their secondary prevention (see fig. 1).
Data Evaluation and Statistics
After a final consistency check with the source data at site, the
questionnaires were sent to the data management centers at the Uni-
versity of Essen and the Stiftung Deutsche Schlaganfall-Hilfe, Gü-
tersloh, where they were rechecked by two physicians for accuracy
and entered into the data bank by trained personnel. Missing or ques-
tionable data were reinvestigated by the local neurologist. Monthly
reports and clinical site visits further ensured data quality.
284 Cerebrovasc Dis 2003;15:282–288 Hamann/Weimar/Glahn/Busse/Diener
Fig. 1. Patients in the German Stroke Data
Bank included in this study.
8,200 Total number of patients with TIA or
ischemic stroke included in the German
Stroke Data Bank
Excluded2,981
5,219 Number of patients from centers meeting
the high data quality criteria
No available information on secondary
prevention
215 Died
219
4,785 Complete data sets available at discharge
No available information on secondary
prevention at follow-up after 3 months
204 Died
1,161
3,240 Complete data sets available at follow-up
after 3 months
No available information on secondary
prevention at follow-up after 1 year
155 Died
625
2,640 Complete data sets available at follow-up
after 1 year
If the patient did not consent to submission of his personal data,
the participating center forwarded only anonymous data to the data
management center, and performed the follow-up interview on site
upon bimonthly request. Otherwise, the follow-up at 3 and 12
months was performed by central telephone interview. If the patient
could not be reached via telephone or his physician, a follow-up letter
was sent. If no information on patient outcome could still be
obtained, the citizen registry was checked for current address or
death.
Categorical variables are presented as percentages. Comparisons
of categorical variables between different medications were per-
formed with the ¯2 test, according to Pearson, with 1 degree of free-
dom. Statistical analyses were performed using the program package
SPSS version 9.0.
Results
According to the distribution of secondary stroke pre-
ventive strategies at discharge from hospital, only 117
patients (2.5%) had no medication to prevent stroke
recurrence. Antiplatelet drugs were used in the majority
of patients (3,429 patients = 71.7%). Various forms of
anticoagulation (i.v. heparin, s.c. heparin or oral antico-
agulation) were used in 1,239 patients (25.9%).
After 3 months, at first follow-up, complete data sets
were available for 3,420 patients. Only 60 patients (1.6%)
received no secondary prevention treatment. The majori-
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Table 1. Adherence to aspirin in patients 3 months after the initial
event, changes to secondary medications
Patients Percent
Still on aspirin 1,617 92.6
Changed to
Clopidogrel 78 4.5
Oral anticoagulation 50 2.8
Ticlopidine 29 1.7
No secondary prevention 23 1.3
Total 1,744a
Some patients were using several secondary preventive strategies
simultaneously, therefore the total percentage exceeds 100%.
a On aspirin at discharge from hospital and followed-up after 3
months.
Table 2. Adherence to aspirin in patients 1 year after the initial
event, changes to secondary medications
Patients Percent
Still on aspirin 1,134 84
Changed to
Clopidogrel 103 7.6
Oral anticoagulation 53 3.9
Ticlopidine 22 1.6
No secondary prevention 61 4.5
Total 1,350a
Some patients were using several secondary preventive strategies
simultaneously, therefore the total percentage exceeds 100%.
a On aspirin at discharge from hospital and followed-up after 3 and
12 months.
ty of patients was still using aspirin. Of 1,747 patients
treated at discharge with aspirin in doses between 80 and
325 mg, according to the recommendations of the Ameri-
can Heart Association (AHA), 1,617 patients (92.6%)
were still taking aspirin after 3 months. Table 1 shows the
change in secondary prevention for all patients receiving
aspirin at discharge from the index hospital stay.
Of 262 patients discharged on ticlopidine, only 183
patients (69.8%) were still taking ticlopidine after 3
months, while 65 patients (24.8%) had switched to aspirin
and 14 patients (5.3%) to clopidogrel.
Of 553 patients discharged on clopidogrel, 452 pa-
tients (81.6%) were still taking this medication after 3
months, and 120 patients (21.7%) were on aspirin. (The
numbers may exceed 100% due to some cases using more
than one preventive medication simultaneously, for ex-
ample the combination of aspirin and clopidogrel).
647 patients took oral anticoagulation at discharge,
and 551 patients (85.2%) were still taking anticoagulants
after 3 months. Only 65 patients (10%) had changed to an
antiplatelet agent, while both strategies were used in 28
patients (4.3%).
Of 46 patients without any secondary stroke pre-
vention at discharge, 24 patients took an antiplatelet
agent after 3 months and 2 patients were on oral anticoag-
ulants.
A total of 2,640 patients could be followed up after 1
year. At this time, only 116 patients (4.4%) did not take
any medication for stroke prevention. The majority of
1,968 patients (74.5%) was on antiplatelet agents and 532
patients (20.2%) were on oral anticoagulation.
Of 1,350 patients on aspirin, the largest group on a sin-
gle medication at discharge, 1,184 patients (84%) were
still taking aspirin after one year. Table 2 depicts the
changes from aspirin to other strategies, especially em-
phasizing clopidogrel as an alternative medication.
Of 197 patients initially discharged on ticlopidine, 104
patients (52.8%) were still taking this medication after
one year, while 70 patients (35,5%) had changed to aspi-
rin and 26 patients (13,2%) to clopidogrel. In the clopido-
grel group, 261 of 424 patients (61.6%) were still on clopi-
dogrel, while 132 (31.1%) had changed to aspirin and 25
(5.9%) to oral anticoagulation.
Unexpectedly, 401 of 518 patients (77.4%) discharged
on oral anticoagulation were still on this medication after
one year, and 86 (16.6%) had switched to aspirin as the
main alternative.
During the study period, the German drug administra-
tion authority did not approve the combination of aspirin
plus dipyridamole.
The causes of death were defined in 204 patients who
died at 3 months: 67 (32.8%) died from their initial stroke
or a recurrent cerebrovascular event, 7 (3.4%) died follow-
ing an intracerebral bleeding, 35 (17.2%) died from
another vascular event, 51 (25%) died from a non-vascu-
lar disease, and in 44 (21.6%) patients the cause of death
was unknown.
Another 40 patients (25.8%) died between 3 months
and one year from the cerebrovascular disease: 3 (1.9%)
from an intracerebral haemorrhage, 26 (16.8%) from a
vascular event, 56 (36.1%) from a nonvascular disease
and in 30 patients (19.4%) the underlying cause of death
was unknown.
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The group of the patients which were followed for the
whole study period (non-dropout group) and those who
could not be followed (dropout group) differed signifi-
cantly by the initial NIHSS (4.7 vs. 6.5, p ! 0.05) and the
gender distribution (male 76.1% vs. female 73.1%, p !
0.05), the age distribution was similar.
The stroke recurrence rate in the adherent group was
6.8% in patients without a change in their secondary pre-
vention regimen.
Discussion
This evaluation of the German Stroke Data Bank
revealed an unexpectedly high adherence to secondary
stroke prevention. 2,460 patients were surveyed until one
year after their stroke, and only 4% did not use any kind
of antithrombotic medication for secondary stroke pre-
vention.
Compared to other fields in cardiovascular medicine
where the rate of adherence was reported as substantially
lower [30], 96% adherence for any stroke prevention is an
extremely high rate. How can this be explained?
First, the German Stroke Data Bank includes only
patients from the leading stroke care centers. Most pa-
tients were briefed extensively on the disease, its underly-
ing causes, the importance of stroke prevention and the
disastrous results of non-adherence. Providing ongoing
health care, from the acute care facility to the rehabilita-
tion center and the primary physician, is standard prac-
tice in Germany. These possible reasons would increase
the demand for excellent stroke management. This would
also suggest, moreover, further evidence for the correla-
tion between low-adherence and sub-optimal patient care
[23, 31–33].
Second, our method of self-reporting adherence could
overestimate the actual adherence. Interviewing patients
by telephone, a frequently used indirect method, has a low
accuracy [34]. Other indirect methods in use are thera-
peutic outcome, pill count, and computerized compliance
monitoring [17, 27, 28, 35, 36]. More sophisticated meth-
ods such as electronic distribution devices, physician or
patient records, and inventories appear advantageous
compared to simple self-report or interview technique
[29, 36]. Objective methods, such as plasma level deter-
mination of a drug, detection of metabolites in urine, sali-
va or blood, and detection of effects caused by the drug
under investigation [37, 38] proved to be the most reliable
monitoring of drug adherence [10, 34]. However, it was
suggested that a satisfactory data quality on adherence
can be expected when patients are personally interviewed
or called by telephone [39, 40]. No rigorous comparison
between indirect methods, like that used in our study, and
objective methods are available yet. In large scale studies,
like the German Stroke Data Bank, interviews or self-
reports are the only workable adherence detection meth-
ods, since objective methods are too costly. Other inex-
pensive methods like online information from local phar-
macies and/or general practitioners are prohibited by law
in Germany or impossible with aspirin as a free over the
counter medication. Taking into account a 10% error
margin on telephone interviews, an 85% adherence rate
still reflects the upper range of reports on patient adher-
ence [11].
Third, the relative high loss of patients at the two fol-
low-up steps may also be responsible for the high adher-
ence, since the adherence in non-reporting patients may
be much weaker than in the patient group still participat-
ing in the follow-up. The two groups of patient (dropout
and non-dropout) did not differ in age, but the dropout
group had slightly more females and more severe initial
NIHSS. How stroke severity affects adherence is not
determined until now. The loss of patients at the different
follow-up steps is high, but in large scale well-performed
and well-controlled pharmaceutical trials, similar rates
for non-compliance with very low dropout rates were
reported [6, 7]. In CAPRIE [6] 21.2% (4,059 out of
19,185) of all patients stopped taking the trial medication,
the loss of patients was 0.13% (49 patients). In ESPS-2
1,690 out of 7,054 patients stopped the continuous intake
of the trial medication, 452 wrong entries were reported
and 0.6% (42 patients) were lost, in total 31% of the
patients which entered the initial study were not included
in the final data analysis [7].
The reported adherence implies that the patient is still
taking the respective medication, but not every single
dose. In studies on drug adherence using electronic rec-
ords, only 50–60% of all patients took exactly the pre-
scribed medication, while 5–10 % did not take any medi-
cation. Approximately 30–45% experienced setbacks, but
took most of the medication [41]. Data concerning the
daily adherence to medication used for secondary stroke
prevention cannot be provided.
Besides compliance to medication, adherence is a
term, implying many other different components. Non-
compliance may be a major cause of non-adherence, but
other complex medical, psychological and social in-
fluences may also result in non-adherence. We are of
course not able to differentiate between the various vari-
ables in this large-scale study. Therefore, we need specific
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observational studies with limited numbers of partici-
pants to further clarify the influences on adherence, and
to quantify the impact of non-compliance as a cause of
non-adherence in stroke prevention. The stroke recur-
rence rate was 6.8% in the first year after the initial stroke
and at the lower margin of an expected rate.
The results of this study concerning individual drugs
prove especially important for three medication regi-
mens: aspirin, thienopyridines and oral anticoagulation.
Adherence to aspirin is favorable and higher than to
any other drug used for secondary stroke prevention in
Germany. While this reflects most recent scientific rec-
ommendation [4, 5, 42, 43], high aspirin adherence may
also result from socioeconomic pressure, which hinders
primary care physicians from using more expensive drugs
like thienopyridines. The change pattern to other regi-
mens gives some insight into the reasons for non-adher-
ence. Patients who switched to clopidogrel, ticlopidin or
oral anticoagulation experienced either new cerebral
events or side effects from aspirin therapy (in total 13.1%
after one year). Only 4.5% were thought to be non-com-
pliant and stopped any secondary prevention. Non-adher-
ence to aspirin after one year can therefore basically
explained by medical reasons in 75% of patients, while
only approximately 25% of patients appeared non-com-
pliant.
Adherence to clopidogrel and ticlopidin as typical thie-
nopyridines was much weaker than adherence to aspirin,
but most patients who changed their medication switched
to aspirin. Therefore, non-adherence to thienopyridines is
most likely not the effect of non-compliance. Medical rea-
sons, side effects, and also socioeconomic problems may
account for the high rate of patients who changed to less
expensive aspirin.
Oral anticoagulation is thought to be potentially more
harmful and also less convenient for patients because of
the need for frequent coagulation controls. When patients
were discharged on oral anticoagulants from the primary
stroke care center [44], adherence was high and even after
one year close to 80%, second after aspirin. This might be
explained by the common scientific consensus, that anti-
coagulants are first choice in atrial fibrillation and car-
dioembolism, and therefore are less likely to be changed
by the treating primary care physician.
Data concerning other secondary stroke prevention
strategies like blood pressure control, smoking cessation,
and treatment of lipid metabolism disorders from the
German Stroke Data Bank are in preparation to be
reported.
Conclusions
In summary, our study provides adherence data to
stroke preventive medication in a large cohort of stroke
patients in Germany. It demonstrates that a surprisingly
high number of patients is adherent to any form of medi-
cal stroke prevention after one year. Aspirin is most wide-
ly used and best adhered to after 3 months and one year.
Almost 85% of patients who initially received the drug are
still taking it one year later. Oral anticoagulation adher-
ence is similar to aspirin adherence, while the thienopy-
ridines depict a reduced adherence of about 60% after one
year. Limited financial resources may account for this
finding. In general, non-adherence may be linked to var-
ious social, medical, and personal factors. Although ad-
herence to secondary stroke prevention strategies in our
study seems high, further research needs to clarify the
underlying factors responsible for non-adherence.
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